-- Wedbush Securities週三發布的一份報告指出，羅技國際（LOGI）在第四財季展現了穩健的營運模式，其在產品創新、成本控制和供應鏈優化方面的強勁執行力，推動了毛利率和營業利潤率的超預期增長。 報告稱，該公司正持續推動其策略重點，包括拓展B2B業務、提升中國市場份額、重振視訊協作業務，以及鞏固其在個人工作空間解決方案領域的領先地位。 Wedbush分析師表示，儘管PC出貨量疲軟且零件成本上漲，羅技仍透過新產品和改進行銷策略提升了平均售價，其中G Pro X2 Superstrike的強勁需求凸顯了其高端產品和遊戲業務的成長。 分析師指出，羅技在PC市場擁有龐大的「空白市場」機會，且升級滲透率較低，因此，改善行銷策略可望推動成長，而淨現金流足以支持其股票回購、分紅和收購活動直至2027年。 Wedbush維持對羅技股票的「跑贏大盤」評級，目標價為135美元。
Price: $102.55, Change: $-2.87, Percent Change: -2.72%
Aptiv (APTV) stock sell-off post Q1 results was unwarranted and likely driven by the lower-than-expected Q2 guide and rising cost pressures with 2026 more back-half weighted that appears like a steep ramp, UBS said in a Wednesday research report.While Q2 is impacted by "stranded cost" and Ford Motor (F) volume timing, H2 ramp looks more achievable than optics suggest amid positive developments in China and the non-auto segments, analysts wrote.The company expects positive growth from China in Q2, driven by new programs and normalization of production at key customer, the brokerage stated.Commodity headwinds should abate in H2 as recoveries lag, UBS said.The brokerage said it reiterated its buy rating on the stock and price target of $80 per share.Aptiv shares were up 4% in Wednesday trading.Price: $56.47, Change: $+1.64, Percent Change: +2.99%
Price: $15.79, Change: $-4.34, Percent Change: -21.55%
Ocular Therapeutix (OCUL) is moving closer to a potential US Food and Drug Administration filing for axpaxli, its long-acting treatment for wet age-related macular degeneration, as regulators begin formal discussions on a single-trial approval path, RBC Capital Markets said Tuesday in a report.Management said talks with the FDA are now ongoing, raising the possibility of submitting an application based on the company's successful pivotal study, rather than waiting for a second trial that is due to read out in early 2027, RBC said.The company plans to provide additional regulatory and program updates at an investor day on June 17, RBC said.Ocular continues to target a potential 2027 launch for axpaxli under a single-trial filing strategy, and RBC reiterated its view that the drug has a "positive benefit/risk profile."RBC maintained its rating of outperform, speculative risk, on Ocular stock with a $30 price target.Price: $9.84, Change: $+0.13, Percent Change: +1.29%